Substituted quinazolinone compounds

Details Substituted quinazolinone compounds Substituted quinazolinone compounds

2004-05-21

2009-12-01

Wilson, James O (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S266310, C544S284000, C544S286000, C544S287000

Reexamination Certificate

active

07625909

ABSTRACT:
A variety of small molecule, guanidine-containing molecules capable of acting as MC4-R agonists are provided. The compounds are useful in treating MC4-R mediated diseases when administered to subjects. The compounds have the structure IA, IB, and IC where the values of the variables are defined herein.

REFERENCES:
patent: 3177218 (1965-04-01), Brown
patent: 4128643 (1978-12-01), Merkel et al.
patent: 4211867 (1980-07-01), Rasmussen
patent: 4287341 (1981-09-01), Hess et al.
patent: 4496571 (1985-01-01), Yellin et al.
patent: 4626537 (1986-12-01), Dave et al.
patent: 4732916 (1988-03-01), Satoh et al.
patent: 4748165 (1988-05-01), Jones et al.
patent: 4874864 (1989-10-01), Schnur et al.
patent: 4948891 (1990-08-01), Schnur et al.
patent: 4948901 (1990-08-01), Schnur et al.
patent: 5086057 (1992-02-01), Sasagawa
patent: 5124328 (1992-06-01), Fisher et al.
patent: 5352704 (1994-10-01), Okuyama et al.
patent: 5362902 (1994-11-01), Bamish et al.
patent: 5547966 (1996-08-01), Atwal et al.
patent: 5637439 (1997-06-01), Kaneko et al.
patent: 5731408 (1998-03-01), Hadley et al.
patent: 5750573 (1998-05-01), Bianchi et al.
patent: 5885985 (1999-03-01), Macdonald et al.
patent: 5889025 (1999-03-01), Lohray et al.
patent: 5952381 (1999-09-01), Chen et al.
patent: 5962530 (1999-10-01), Engel et al.
patent: 6020349 (2000-02-01), Ankerson et al.
patent: 6030985 (2000-02-01), Gentile et al.
patent: 6054556 (2000-04-01), Huby et al.
patent: 6060589 (2000-05-01), Stark et al.
patent: 6127343 (2000-10-01), Andersen et al.
patent: 6180603 (2001-01-01), Frey, II
patent: 6225331 (2001-05-01), Cupps et al.
patent: 6297233 (2001-10-01), Stein et al.
patent: 6313093 (2001-11-01), Frey, II
patent: 6391878 (2002-05-01), Cupps et al.
patent: 6638927 (2003-10-01), Renhowe et al.
patent: 6716840 (2004-04-01), Chu et al.
patent: 6995269 (2006-02-01), Renhowe et al.
patent: 7034033 (2006-04-01), Boyce et al.
patent: 7368453 (2008-05-01), Boyce et al.
patent: 2003/0195187 (2003-10-01), Boyce et al.
patent: 2003/0207814 (2003-11-01), Boyce et al.
patent: 2003/0229025 (2003-12-01), Xiao et al.
patent: 2004/0019049 (2004-01-01), Boyce et al.
patent: 2006/0235019 (2006-10-01), Boyce et al.
patent: 31 08 322 (1981-12-01), None
patent: 0343894 (1989-11-01), None
patent: WO 96/24580 (1996-08-01), None
patent: WO 97/19911 (1997-06-01), None
patent: WO 97/41119 (1997-11-01), None
patent: WO 98/07420 (1998-02-01), None
patent: WO 98/23596 (1998-06-01), None
patent: WO 99/64002 (1999-12-01), None
patent: WO 00/03973 (2000-01-01), None
patent: WO 00/17191 (2000-03-01), None
patent: WO 00/74679 (2000-12-01), None
patent: WO 01/04103 (2001-01-01), None
patent: WO 01/10842 (2001-02-01), None
patent: WO 01/55106 (2001-08-01), None
patent: WO 01/55107 (2001-08-01), None
patent: WO 01/55109 (2001-08-01), None
patent: WO 01/70337 (2001-09-01), None
patent: WO 01/70708 (2001-09-01), None
patent: WO 02/18327 (2002-03-01), None
patent: WO 02/062776 (2002-08-01), None
patent: WO 02/081443 (2002-10-01), None
patent: WO 03/072056 (2003-09-01), None
patent: WO 03/099818 (2003-12-01), None
patent: WO 2005/051391 (2005-06-01), None
Wagner, J. G. “Intrasubject Variation in Elimination Half-Lives of Drugs . . . ” Journal of Pharmacokinetics and Biopharmaceutics, 1973, vol. 1, No. 2, pp. 165-173.
Julia, M. et al., “Amidines and guanidines related to congocidine. III. Urea and trazene diamidines,”Bull. Soc. Chim. Fr., No. 1, pp. 376-382, 1968, published by Masson Editeur, Paris, France.
Mountjoy, K. G. et al., “The Cloning of a Family of Genes That Encode the Melanocortin Receptors,”Science,vol. 257, pp. 1248-1251, Aug. 28, 1992.
Lu, D. et al., “Agouti protein is an antagonist of the melanocyte-stimulating-hormone receptor,”Nature,vol. 371, pp. 799-802, Oct. 27, 1994.
Huszar, D. et al., “Targeted Disruption of the Melanocortin-4 Receptor Results in Obesity in Mice,”Cell,vol. 88, pp. 131-141, Jan. 10, 1997, published by Cell Press.
Ollmann, M. M. et al., “Antagonism of Central melanocortin Receptors in Vitro and in Vivo by Agouti-Related Protein,”Science,vol. 278, pp. 135-138, Oct. 3, 1997.
Kiefer, L.L. et al., “Mutations in the Carboxyl Terminus of the Agouti Protein Decrease Agouti Inhibition of Ligand Binding to the Melanocortin Receptors,”Biochemistry,vol. 36, pp. 2084-2090, 1997, published by American Chemical Society.
Fong, T. M. et al., “ART (Protein Product of Agouti-Related Transcript) as an Antagonist of MC-3 and MC-4 Receptors,”Biochemical and Biophysical Res. Comm.,vol. 237, pp. 629-631, 1997, published by Academic Press.
Asagarasu, A. et al., “Synthesis of Dipeptide-Type Human Immunodeficiency Virus (HIV) Protease Inhibitors with a Binding Unit to GP120,”Chem. Pharm. Bull.,vol. 46, No. 5, pp. 867-870, 1998, published by Pharmaceutical Society of Japan.
Rossi, M. et al., “A C-terminal fragment of Agouti-related protein increases feeding and antagonizes the effect of alpha-melanocyte stimulating hormone in vivo,”Endocrinology,vol. 139, No. 10, pp. 4428-4431, 1998. published by The Endocrine Society.
Hadley, M. E. et al., “The Proopiomelanocortin System,”Ann. N. Y. Acad. Sci.,885:1, pp. 1-21, 1999.
Smolnik, R. et al., “Brain Potentials and Attention after Acute and Subchronic Intranasal Administration of ACTH 4-10 and Desacetyl-α-MSH in Humans,”Neuroendocrinology,vol. 70, pp. 63-72, 1999, published by S. Karger AG, Basel.
Fehm, H. L. et al., “The Melanocortin Melanocyte-Stimulating Hormone/Adrenocorticotropin4-10Decreases Body Fat in Humans,”J. Clin. Endocrinology&Metabolism,vol. 86, No. 3, pp. 1144-1148, 2001, published by the Endocrine Society.
Smith, R. A. et al., “Discovery and Parallel Synthesis of a New Class of Cathepsin K Inhibitors,”Bioorganic&Medicinal Chemistry Letters,vol. 11, pp. 2951-2954, 2001, published by Elsevier Science Ltd.
Shadiak, A. M. et al. “Intranasal Delivery of a Melanocortin for the Treatment of Sexual Dysfunction,” Presentation at Fifth International Conference Exploring the Rapidly Developing Area of Nasal Drug Delivery, Mar. 21 and 22, Le Meridien Hotel, Piccadilly, London, United Kingdom., 2002.
Runti, C.; DeNardo, M.; Ulian F., “Fusaric Acid Derivatives and Analogues as Possible Antihypertensive Drugs,” II Farmaco Edizione Scientifica, vol. 36(4), pp. 260-268(1981), published in Italy by the Society of Italian Pharmaceutical Science. This is an English-language document.
Wolff, M. E., “Burger's Medicinal Chemistry and Drug Discovery 5thEdition,” pp. 975-977 (1995), M. E. Wolff (ed.); published by John Wiley & Sons (New York, NY).
Banker, G. S. et al., “Modern Pharmaceutics, 3rdEdition,” pp. 596 and 451 (1996), G. S. Banker and C. T. Rhodes (eds.); published by Marcel Dekker, Inc. (New York, NY).
West, A. R., “Solid State Chemistry and Its Applications,” pp. 358 and 365 (1988), A. R. West (ed.); published by John Wiley & Sons (New York, NY).
Goodfellow, V. S. et al., “The Melanocortin System and its Role in Obesity and Cachexia,”Current Top. Med. Chem.,vol. 3, No. 8, pp. 855-883 (2003); published by Bentham Science Publishers Ltd. (San Francisco, CA).
Fisher, S. L. et al., Int. J. Obes. Relat. Metab. Disord. Suppl. 1, pp. 54-48 (Feb. 1999); published by the American Dietetic Association (Chicago, IL).
Dörwald, F. Zaragoza, Side Reactions in Organic Synthesis: A Guide to Successful Synthesis Design, Weinheim: Wiley-VCH Verlag GmbH & Co. KGaA, 2005, Preface.
Examination Report for EP 03738964.0 dated Aug. 5, 2008.
Examination Report for EP 03738964.0 dated Jan. 31, 2008.
Jordan, V. C., Nature Reviews: Drug Discovery, 2, pp. 205-213, 2003.
Supplementary European Search Report for Application No. 04811698.2 dated Oct. 7, 2008.
Supplementary European Search Report for EP 03738964.0 dated Jul. 25, 2006.
Vippagunta et al., “Crystalline solids,”Advanced Drug Delivery Reviews, 48, pp.

Affiliated with

Also associated with

Rating

Substituted quinazolinone compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Substituted quinazolinone compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted quinazolinone compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4058483